Interventional News’ most popular stories from May included a forecast of where embolization is headed from a Global Embolization Oncology Symposium (GEST, 18–21 May, New York City, USA) presenter, the announcement of Bentley’s first US product launch and Quantum Surgical’s first US patient treated with the Epione robot, and new data on a range of procedures, from (endo)grafts for abdominal aortic aneurysm (AAA) and haemodialysis, to prostatic urethral lift (PUL) for benign prostatic hyperplasia (BPH).
Varian, a Siemens Healthineers company, is introducing the Isolis cryoprobe, a single-use, disposable device designed for use with CryoCare systems that seeks to improve procedural efficiency and precision for cryoablation. The new Isolis cryoprobe offers the interventional radiologist greater operational control.
Speaking at GEST 2023, Lindsay Machan (University of British Columbia, Vancouver, Canada) gave a comprehensive outlook on the next five years in embolization, outlining procedures that will be characteristic, and the advancements that are needed to propel practice into the future.
The first US patient has been enrolled in the SELUTION4SFA sirolimus drug-eluting balloon (DEB) study by Arthur Lee (Cardiac & Vascular Institute, Gainesville, USA). This study evaluates SELUTION SLR in the treatment of occlusive disease of the superficial femoral artery (SFA) and proximal popliteal artery (PPA).
Endologix has announced the online publication of the final five-year results of the LEOPARD trial in the Journal of Vascular Surgery (JVS). The study’s findings showed that there was no significant difference in aneurysm-related outcomes between patients randomised to the AFX endograft system, with anatomical fixation, and commercially available endografts with proximal fixation.
Vivasure Medical has announced it has enrolled the first patients in the company’s PerQseal PATCH clinical study, a multicentre, single-arm, pivotal study evaluating the safety and efficacy of the Vivasure PerQseal closure device system. The first patients were enrolled at Kaleida Health’s Buffalo General Medical Center-Gates Vascular Institute (Buffalo, USA).
Xeltis has presented “highly-encouraging” six-month data from its first-in-human (FIH) aXess vascular graft trial at the 13th Congress of the Vascular Access Society (VAS; 27–29 April, Porto, Portugal). A press release outlines that six-month data from the FIH trial found that the aXess vascular access graft for haemodialysis demonstrated high patency rates.
Govindarajan Narayanan, chief of interventional oncology at Miami Cancer Institute and a vascular interventional radiologist with Miami Cardiac & Vascular Institute (both Miami, USA), successfully treated the first patient in the USA with a liver tumour using Quantum Surgical’s Epione robot. The procedure took place at Baptist Health South Florida (Miami, USA).
Akura Medical announced today it has initiated its first-in-human clinical study of the Akura mechanical thrombectomy platform—a low-profile solution designed to easily access and efficiently remove large-volume, mixed-morphology clots, and eliminate the guesswork around the procedure. The initial five cases were performed in Bradenton, USA and marked the first use of mechanical thrombectomy for pulmonary embolism (PE) in the country.
Teleflex has announced new research findings reinforcing the long-term durability of PUL with the UroLift system and lower complication rates compared to other minimally invasive procedures for men with enlarged prostate, also called BPH.